Gastrointestinal Stromal Tumor

Fluorescence in situ hybridization (FISH) revealed EWSR1 gene rearrangement, and next-generation sequencing (NGS)-based RNA fusion gene detection identified EWSR1::ATF1 fusion, supporting the diagnosis of MGNET. We will discuss the abnormal immunophenotype and differential diagnosis of MGNET, reviewing relevant literature.

Addressing these challenges requires​ thorough correlation with clinical and radiological findings, combined application of both immunohistochemical markers, and proactive genetic testing for cases with atypical immunohistochemical profile. These measures are crucial for improving diagnostic accuracy and guiding targeted therapies.

Nevertheless, several challenges remain, including receptor heterogeneity, physiologic uptake in normal tissues, optimization of pharmacokinetics, the complexity of dual-targeted constructs, and the lack of high-quality prospective clinical evidence. Future progress will likely depend on ligand engineering, dual-target strategies, individualized dosimetry, and the integration of imaging-based treatment assessment into a closed-loop precision theranostic framework.

Multivariate analysis showed that a distance from the lesion center to the ligament of Treitz of 85 mg/L (OR=6.168, 95%CI: 1.514-25.128, P=0.007) were independent risk factors for PPOI after segmental jejunal resection. Patients undergoing proximal jejunal resection, defined as a distance from the lesion center to the ligament of Treitz of <30 cm, as well as those with postoperative hypokalemia and elevated C-reactive protein levels, are at a higher risk of developing PPOI.

Genome-wide SNP-based LOH profiling reveals distinct, subgroup-specific patterns of chromosomal imbalance in GIST and may serve as a feasible complementary approach to driver mutation analysis for refined molecular characterization and potential future clinical utility.

Elevated Cx43 expression may contribute to the poor prognosis of patients with SI-GISTs by enhancing their metastatic potential. Cx43 represents a potential novel therapeutic target for the inhibition of SI-GIST metastasis.

In a large cohort of women with cancer who underwent multigene testing, SDHx PV/LPV carriers did not show higher BC prevalence than the overall group, and age at diagnosis was similar. The proportion of breast cancer in SDHx carriers was lower, but it remains unclear whether their risk differs from the general population or if findings are incidental. Since SDHx is often found incidentally, breast care teams should prioritize surveillance for tumors known to be associated with SDHx (PPGL, RCC, and GIST) and refer patients as appropriate to genetics or specialty care. Further prospective studies with cancer-free controls are needed to define breast cancer risk in SDHx carriers and guide screening.

The first regulatory approval of an Hsp90 inhibitor, Pimitespib, for refractory gastrointestinal stromal tumor, marks a translational milestone that validates this framework clinically. Combination studies have further mapped where Hsp90 inhibition is most informative and most effective, demonstrating that benefit is strongest when deployment is guided by defined client dependency, proteostasis burden, immune context, or biomarker selection. Together, these advances position Hsp90 inhibitor research as a major source of mechanistic insight into molecular chaperones and as a foundation for biomarker-guided, context-aware targeting of proteostasis in oncology and beyond.

Despite overlapping pathological features, uterine and gastrointestinal stromal tumors differ clinically. Surgery is the primary treatment; comprehensive preoperative imaging and postoperative pathological examination are critical to prevent misdiagnosis and optimize management.

P3, N=482, Recruiting, Cogent Biosciences, Inc. | Active, not recruiting --> Recruiting

The patient recovered uneventfully with resolution of bleeding and normalization of hemoglobin. This case highlights the importance of considering small bowel GIST in unexplained melena and severe anemia and demonstrates the curative potential of timely surgical resection in localized low-risk disease.

P=N/A, N=750, Active, not recruiting, M.D. Anderson Cancer Center | Trial completion date: Jan 2026 --> Jan 2028 | Trial primary completion date: Jan 2026 --> Jan 2028